📝 shorten desc to meet length requirements

STUDY_CONFIGS/tll_sd_aq9kvn5p_2019_case_meta_config.json

@@ -166,7 +166,7 @@
     },
     "study": {
         "_comment": "see https://docs.cbioportal.org/5.1-data-loading/data-loading/file-formats#cancer-study for detailed specifics",
-        "description": "This study focuses on improving the treatment of relapsed T-cell acute lymphoblastic leukemia (T-ALL), a type of blood cancer with a poor prognosis. Currently, it is challenging to identify patients at high risk of relapse at the time of diagnosis. The study analyzes the genetic makeup of T-ALL patients from a clinical trial (AALL0434) to find genetic alterations that could help predict poor outcomes and guide alternative treatments. The research uses comprehensive genomic profiling techniques like RNA sequencing, DNA CNV analysis, WXS, and WGS. The specific goals are to identify recurrent genetic alterations associated with poor prognosis, discover novel genetic changes, and find germline genetic variants that make patients more susceptible to T-ALL and increased chemotherapy toxicity. The findings aim to advance our understanding of T-ALL and provide insights for better risk stratification and personalized therapies. KF, GMKF. For updates, please see here: <a href=\"https://tinyurl.com/55cxz9am\">Release Notes</a>",
+        "description": "This study focuses on improving the treatment of relapsed T-cell acute lymphoblastic leukemia (T-ALL), a type of blood cancer with a poor prognosis. Currently, it is challenging to identify patients at high risk of relapse at the time of diagnosis. The study analyzes the genetic makeup of T-ALL patients from a clinical trial (AALL0434) to find genetic alterations that could help predict poor outcomes and guide alternative treatments. The research uses comprehensive genomic profiling techniques like RNA-seq, DNA CNV analysis, WXS, and WGS. The specific goals are to identify recurrent genetic alterations associated with poor prognosis, discover novel genetic changes, and find germline genetic variants that make patients more susceptible to T-ALL and increased chemotherapy toxicity. The findings aim to advance our understanding of T-ALL and provide insights for better risk stratification and personalized therapies. KF, GMKF. For updates, please see here: <a href=\"https://tinyurl.com/55cxz9am\">Release Notes</a>",
         "groups": "PUBLIC",
         "cancer_study_identifier": "tll_sd_aq9kvn5p_2019",
         "type_of_cancer": "tll",